CD123 CAR-T cell therapy(Chongqing Precision Biotechnology)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCD123 CAR-T cell therapy(Chongqing Precision Biotechnology)
Drug Alias NameAnti-CD123 chimeric antigen receptor T cell therapy (Chongqing Precision Biotech)Anti-CD123 CAR-T cell therapy (Chongqing Precision Biotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmLeukemia, Myeloid, AcuteLeukemia, Myeloid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChongqing Precision Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChongqing Precision Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmLeukemia, Myeloid, AcuteLeukemia, Myeloid +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A